NCT00850161View on ClinicalTrials.gov

Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

September 30, 2010

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

aspart

Meal-time insulin. Administered subcutaneously based on routine clinical therapy.

DRUG

Nasulin™

100 IU(2 puffs in each nostril)

Sponsors
All Listed Sponsors
lead

CPEX Pharmaceuticals Inc.

INDUSTRY